108 related articles for article (PubMed ID: 22429066)
1. Short-term (2-week) effects of discontinuing milnacipran in patients with fibromyalgia.
Saxe PA; Arnold LM; Palmer RH; Gendreau RM; Chen W
Curr Med Res Opin; 2012 May; 28(5):815-21. PubMed ID: 22429066
[TBL] [Abstract][Full Text] [Related]
2. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial.
Clauw DJ; Mease P; Palmer RH; Gendreau RM; Wang Y
Clin Ther; 2008 Nov; 30(11):1988-2004. PubMed ID: 19108787
[TBL] [Abstract][Full Text] [Related]
3. Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial.
Clauw DJ; Mease PJ; Palmer RH; Trugman JM; Wang Y
Arthritis Res Ther; 2013 Aug; 15(4):R88. PubMed ID: 23953493
[TBL] [Abstract][Full Text] [Related]
4. Milnacipran effects on 24-hour ambulatory blood pressure and heart rate in fibromyalgia patients: a randomized, placebo-controlled, dose-escalation study.
Trugman JM; Palmer RH; Ma Y
Curr Med Res Opin; 2014 Apr; 30(4):589-97. PubMed ID: 24188161
[TBL] [Abstract][Full Text] [Related]
5. Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study.
Goldenberg DL; Clauw DJ; Palmer RH; Mease P; Chen W; Gendreau RM
Pain Med; 2010 Feb; 11(2):180-94. PubMed ID: 20002596
[TBL] [Abstract][Full Text] [Related]
6. A 3-year, open-label, flexible-dosing study of milnacipran for the treatment of fibromyalgia.
Arnold LM; Palmer RH; Ma Y
Clin J Pain; 2013 Dec; 29(12):1021-8. PubMed ID: 23446068
[TBL] [Abstract][Full Text] [Related]
7. A pooled analysis of two randomized, double-blind, placebo-controlled trials of milnacipran monotherapy in the treatment of fibromyalgia.
Geisser ME; Palmer RH; Gendreau RM; Wang Y; Clauw DJ
Pain Pract; 2011; 11(2):120-31. PubMed ID: 20642487
[TBL] [Abstract][Full Text] [Related]
8. Relationships among pain, depressed mood, and global status in fibromyalgia patients: post hoc analyses of a randomized, placebo-controlled trial of milnacipran.
Arnold LM; Palmer RH; Gendreau RM; Chen W
Psychosomatics; 2012; 53(4):371-9. PubMed ID: 22677218
[TBL] [Abstract][Full Text] [Related]
9. Preliminary experience using milnacipran in patients with juvenile fibromyalgia: lessons from a clinical trial program.
Arnold LM; Bateman L; Palmer RH; Lin Y
Pediatr Rheumatol Online J; 2015 Jun; 13():27. PubMed ID: 26112278
[TBL] [Abstract][Full Text] [Related]
10. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia.
Vitton O; Gendreau M; Gendreau J; Kranzler J; Rao SG
Hum Psychopharmacol; 2004 Oct; 19 Suppl 1():S27-35. PubMed ID: 15378666
[TBL] [Abstract][Full Text] [Related]
11. Effects of milnacipran on the multidimensional aspects of fatigue and the relationship of fatigue to pain and function: pooled analysis of 3 fibromyalgia trials.
Mease PJ; Palmer RH; Wang Y
J Clin Rheumatol; 2014 Jun; 20(4):195-202. PubMed ID: 24847745
[TBL] [Abstract][Full Text] [Related]
12. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial.
Matthey A; Cedraschi C; Piguet V; Besson M; Chabert J; Daali Y; Courvoisier D; Montagne A; Dayer P; Desmeules JA
Pain Physician; 2013; 16(5):E553-62. PubMed ID: 24077206
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial.
Arnold LM; Gendreau RM; Palmer RH; Gendreau JF; Wang Y
Arthritis Rheum; 2010 Sep; 62(9):2745-56. PubMed ID: 20496365
[TBL] [Abstract][Full Text] [Related]
14. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia.
Branco JC; Zachrisson O; Perrot S; Mainguy Y;
J Rheumatol; 2010 Apr; 37(4):851-9. PubMed ID: 20156949
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.
Mease PJ; Clauw DJ; Gendreau RM; Rao SG; Kranzler J; Chen W; Palmer RH
J Rheumatol; 2009 Feb; 36(2):398-409. PubMed ID: 19132781
[TBL] [Abstract][Full Text] [Related]
16. Milnacipran and pindolol: a randomized trial of reduction of antidepressant latency.
Isaac MT; Isaac MB; Gallo F; Tournoux A
Hum Psychopharmacol; 2003 Dec; 18(8):595-601. PubMed ID: 14696018
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
18. Milnacipran: in fibromyalgia.
Chwieduk CM; McCormack PL
Drugs; 2010; 70(1):99-108. PubMed ID: 20030428
[TBL] [Abstract][Full Text] [Related]
19. Effects of milnacipran on clinical pain and hyperalgesia of patients with fibromyalgia: results of a 6-week randomized controlled trial.
Staud R; Lucas YE; Price DD; Robinson ME
J Pain; 2015 Aug; 16(8):750-9. PubMed ID: 25998206
[TBL] [Abstract][Full Text] [Related]
20. Longterm therapeutic response to milnacipran treatment for fibromyalgia. A European 1-year extension study following a 3-month study.
Branco JC; Cherin P; Montagne A; Bouroubi A;
J Rheumatol; 2011 Jul; 38(7):1403-12. PubMed ID: 21459941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]